Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1934
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score ; volume:36 ; number:2 ; day:11 ; month:2 ; year:2022 ; pages:191-202 ; date:2.2022
CNS drugs ; 36, Heft 2 (11.2.2022), 191-202, 2.2022
- Urheber
-
Iannone, Luigi Francesco
Fattori, Davide
Benemei, Silvia
Chiarugi, Alberto
Geppetti, Pierangelo
Cesaris, Francesco De
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40263-021-00893-y
- URN
-
urn:nbn:de:101:1-2022052421402607712012
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.0045, 06:32 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Iannone, Luigi Francesco
- Fattori, Davide
- Benemei, Silvia
- Chiarugi, Alberto
- Geppetti, Pierangelo
- Cesaris, Francesco De
- SpringerLink (Online service)
Ähnliche Objekte (12)
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Monoclonal antibodies for migraine: an update
Inflammatory complications of CGRP monoclonal antibodies: a case series
Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Monoclonal antibodies for migraine: an update
Inflammatory complications of CGRP monoclonal antibodies: a case series
Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Monoclonal antibodies for migraine: an update
Inflammatory complications of CGRP monoclonal antibodies: a case series
Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study